CLINICAL TRIALS PROFILE FOR MAVENCLAD
✉ Email this page to a colleague
All Clinical Trials for MAVENCLAD
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03150004 ↗ | Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia | Recruiting | Medical College of Wisconsin | Phase 2 | 2017-06-14 | This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives. |
| NCT03364036 ↗ | Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) | Active, not recruiting | Merck KGaA, Darmstadt, Germany | Phase 4 | 2018-05-28 | The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS). |
| NCT03369665 ↗ | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) | Active, not recruiting | Merck KGaA, Darmstadt, Germany | Phase 4 | 2018-06-20 | The main purpose of the study is to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months). |
| NCT03441048 ↗ | Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | Medical College of Wisconsin | Phase 1 | 2018-05-22 | This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design to estimate the maximum-tolerated dose (MTD). |
| NCT04121403 ↗ | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) | Recruiting | Göteborg University | Phase 3 | 2019-10-16 | The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies. |
| NCT04121403 ↗ | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) | Recruiting | Helse Forde | Phase 3 | 2019-10-16 | The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAVENCLAD
Condition Name
Clinical Trial Locations for MAVENCLAD
Trials by Country
Clinical Trial Progress for MAVENCLAD
Clinical Trial Phase
Clinical Trial Sponsors for MAVENCLAD
Sponsor Name
| Sponsor Name for MAVENCLAD | |
| Sponsor | Trials |
| Medical College of Wisconsin | 3 |
| Merck KGaA, Darmstadt, Germany | 2 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
